Other Viruses Citation List:

December 23 - January 5, 2012

Hepatitis B virus

1. Chromone Derivatives from Halenia elliptica and Their anti-HBV Activities. Sun, Y.W., G.M. Liu, H. Huang, and P.Z. Yu, Phytochemistry, 2011. [Epub ahead of print]; PMID[22192328].

[Pubmed]. OV_1223-010512.

Hepatitis C virus

2. Mycophenolic acid Augments Interferon-stimulated Gene Expression and Inhibits Hepatitis C Virus Infection in Vitro and in Vivo. Pan, Q., P.E. de Ruiter, H.J. Metselaar, J. Kwekkeboom, J. de Jonge, H.W. Tilanus, H.L. Janssen, and L.J. van der Laan, Hepatology (Baltimore, Md.), 2011. [Epub ahead of print]; PMID[22213147].

[Pubmed]. OV_1223-010512.

3. Synthesis and anti-HCV Activity Evaluation of Anilinoquinoline Derivatives. Peng, H.K., C.K. Lin, S.Y. Yang, C.K. Tseng, C.C. Tzeng, J.C. Lee, and S.C. Yang, Bioorganic & Medicinal Chemistry Letters, 2011. [Epub ahead of print]; PMID[22204909].

[Pubmed]. OV_1223-010512.

4. 2-Hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic Acid with Inbuilt beta-NHydroxy-gamma-keto-acid Pharmacophore as HCV NS5B Polymerase Inhibitors. Deore, R.R., G.S. Chen, C.S. Chen, P.T. Chang, M.H. Chuang, T.R. Chern, H.C. Wang, and J.W. Chern, Current Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[22204334].

[Pubmed]. OV_1223-010512.

5. Identification of Novel N-(Morpholine-4-carbonyloxy) amidine Compounds as Potent Inhibitors against Hepatitis C Virus Replication. Kusano-Kitazume, A., N. Sakamoto, Y. Okuno, Y. Sekine-Osajima, M. Nakagawa, S. Kakinuma, K. Kiyohashi, S. Nitta, M. Murakawa, S. Azuma, Y. Nishimura-Sakurai, M. Hagiwara, and M. Watanabe, Antimicrobial Agents and Chemotherapy, 2011. [Epub ahead of print]; PMID[22203602].

[Pubmed]. OV_1223-010512.

6. In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A. Wang, C., L. Jia, H. Huang, D. Qiu, L. Valera, X. Huang, J.H. Sun, P.T. Nower, D.R. O'Boyle, 2nd, M. Gao, and R.A. Fridell, Antimicrobial Agents and Chemotherapy, 2011. [Epub ahead of print]; PMID[22203595].

[Pubmed]. OV_1223-010512.

7. Synthesis of 1,4-Disubstituted Mono and Bis-triazolocarbo-acyclonucleoside Analogues of 9-(4-Hydroxybutyl)guanine by Cu(I)-Catalyzed Click Azide-Alkyne Cycloaddition. Krim, J., M. Taourirte, and J.W. Engels, Molecules (Basel, Switzerland), 2011. 17(1): p. 179-190; PMID[22202806].

[Pubmed]. OV_1223-010512.

8. Pyridobenzothiazole Derivatives as New Chemotype Targeting the HCV NS5B Polymerase. Manfroni, G., F. Meschini, M.L. Barreca, P. Leyssen, A. Samuele, N. Iraci, S. Sabatini, S. Massari, G. Maga, J. Neyts, and V. Cecchetti, Bioorganic & Medicinal Chemistry, 2011; PMID[22197397].

[Pubmed]. OV_1223-010512.

9. Inhibitory Effects of Polyphenols Toward HCV from the Mangrove Plant Excoecaria agallocha L. Li, Y., S. Yu, D. Liu, P. Proksch, and W. Lin, Bioorganic & Medicinal Chemistry Letters, 2011. [Epub ahead of print]; PMID[22196120].

[Pubmed]. OV_1223-010512.

10. Novel, Potent and Orally Bioavailable Indolizidinone-derived Inhibitors of the Hepatitis C Virus NS3 Protease. Clarke, M.O., D. Byun, X. Chen, E. Doerffler, S.A. Leavitt, X.C. Sheng, C.Y. Yang, and C.U. Kim, Bioorganic & Medicinal Chemistry Letters, 2011. [Epub ahead of print]; PMID[22189140].

[Pubmed]. OV_1223-010512.

Citations from the ISI Web of Knowledge Listings for O.V.

11. In Vitro Profiling of GSK2336805, a Potent and Selective Inhibitor of HCV NS5A. Bechtel, J., R. Crosby, A. Wang, E. Woldu, S. Van Horn, J. Horton, K. Creech, L.H. Caballo, C. Voitenleitner, J. Vamathevan, M. Duan, A. Spaltenstein, W. Kazmierski, C. Roberts, and R. Hamatake, Journal of Hepatology, 2011. 54: p. S307-S308; ISI[000297625601342].

[WOS]. OV_1223-010512.

12. Novel, Potent, Pan-genotypic HCV NS3/4A Protease Inhibitors with a High Barrier to Resistance. Buckman, B.O., K. Kossen, J.B. Nicholas, V. Serebryany, D. Ruhrmund, R. Rajagopalan, S. Misialek, L. Hooi, N. Aleskovski, L. Pan, L. Huang, C.J. Schaefer, S. Rajyaguru, S. Le Pogam, I. Najera, K. Klumpp, and S. Seiwert, Journal of Hepatology, 2011. 54: p. S472-S472; ISI[000297625602335].

[WOS]. OV_1223-010512.

13. Substitution of a Conserved Amino acid in the Transmembrane Domain of E2 Confers Resistance to a Novel Small-molecule Inhibitor of HCV Entry. Coburn, G.A., D.N. Fisch, S. Moorji, J.D. Murga, J.M. de Muys, D. Paul, A.Q. Han, Y. Rotshteyn, D. Qian, P.J. Maddon, and W.C. Olson, Journal of Hepatology, 2011. 54: p. S311-S311; ISI[000297625601352].

[WOS]. OV_1223-010512.

14. Characterization and Identification of PPI-437, PPI-668 and PPI-833 as Potent and Selective HCV NS5A Inhibitors with Activity against all HCV Genotypes. Colonno, R., N. Huang, Q. Huang, E. Peng, A. Huq, M. Lau, M. Bencsik, M. Zhong, and L. Li, Journal of Hepatology, 2011. 54: p. S474-S474; ISI[000297625602339].

[WOS]. OV_1223-010512.

15. Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451. Corsa, A., M. Robinson, H. Yang, B. Peng, G. Cheng, B. Schultz, O. Barauskas, M. Hung, X. Liu, C. Yang, Y. Wang, G. Rhodes, R. Pakdaman, M. Shen, C. Sheng, C. Kim, and W. Delaney, Journal of Hepatology, 2011. 54: p. S313-S313; ISI[000297625601356].

[WOS]. OV_1223-010512.

16. Idenix NS5A HCV Replication Inhibitors with Low Picomolar, Pan-genotypic in Vitro Antiviral Activity. Dousson, C.B., C. Chapron, D. Standring, J.P. Bilello, J. McCarville, M. La Colla, M. Seifer, C. Parsy, D. Dukhan, C. Pierra, and D. Surleraux, Journal of Hepatology, 2011. 54: p. S326-S327; ISI[000297625601393].

[WOS]. OV_1223-010512.

17. Nonclinical and Cross-genotypic Profiles of GS-9669, a Novel HCV NS5B Non-nucleoside Thumb Site II Inhibitor. Fenaux, M., Y. Tian, M. Matles, E. Mabery, J.Y. Zhang, S. Eng, B. Murray, J. Mwangi, S. Lazerwith, W. Lew, E. Canales, Q. Liu, D. Byun, E. Doerffler, H. Ye, M. Clarke, M. Mertzman, P. Morganelli, J. Zhang, S. Leavitt, T. Appleby, A. Hashash, A. Bidgood, S. Krawczyk, and W. Watkins, Journal of Hepatology, 2011. 54: p. S476-S476; ISI[000297625602345].

[WOS]. OV_1223-010512.

18. BMS-766, a Novel HCV NS5A Inhibitor with Enhanced Resistance Coverage. Gao, M., R. Fridell, C. Wang, J.H. Sun, D. O'Boyle, L. Valera, P. Nower, A. Monikowski, M. Kirk, H. Huang, C. Ngo, H. Fang, R. Knox, Y.K. Wang, V. Nguyen, F. Wang, L. Snyder, R. Lavoie, J. Bender, J. Kadow, M. Cockett, N. Meanwell, and M. Belema, Journal of Hepatology, 2011. 54: p. S316-S316; ISI[000297625601365].

[WOS]. OV_1223-010512.

19. GNS-227: A New Potent and Selective HCV NS3 Protease Inhibitor with a High Genetic Barrier to Resistance. Halfon, P., J. Courcambeck, T. Whitaker, M. Bouzidi, T.R. McBrayer, G. Roche, P.M. Tharnish, G. Pepe, R.F. Schinazi, and S.J. Coats, Journal of Hepatology, 2011. 54: p. S478-S478; ISI[000297625602349].

[WOS]. OV_1223-010512.

20. ACH-2928: A Novel Highly Potent HCV NS5A Inhibitor with Favorable Preclinical Characteristics. Huang, M., G. Yang, D. Patel, Y. Zhao, J. Fabrycki, C. Marlor, J. Rivera, K. Stauber, V. Gadhachanda, J. Wiles, A. Hashimoto, D. Chen, Q. Wang, G. Pais, X. Wang, M. Deshpande, and A. Phadke, Journal of Hepatology, 2011. 54: p. S479-S479; ISI[000297625602351].

[WOS]. OV_1223-010512.

21. A Highly Potent HCV NS5A Inhibitor EDP-239 with Favorable Preclinical Pharmacokinetics. Jiang, L.J., S. Liu, T. Phan, C. Owens, B. Brasher, A. Polemeropoulos, X. Luo, K. Hoang, M. Wang, X. Peng, H. Cao, Y. Qiu, and Y.S. Or, Journal of Hepatology, 2011. 54: p. S479-S479; ISI[000297625602352].

[WOS]. OV_1223-010512.

22. Preclinical Characterization of the Hepatitis C Virus NS5B Polymerase Non-nucleoside Inhibitor BILB 1941. Kukolj, G., P.C. Anderson, M. Boes, M.G. Cordingley, R. Coulombe, M. Garneau, J. Gillard, S. Goulet, E. Jolicoeur, L. Lagace, D. Lamarre, S. Laplante, M. Marquis, G. McKercher, C. Pellerin, M.A. Poupart, and P.L. Beaulieu, Journal of Hepatology, 2011. 54: p. S480-S480; ISI[000297625602354].

[WOS]. OV_1223-010512.

23. Highly Potent HCV NS5B Inhibitor with Original Mechanism of Action Identified with the 3D-screen Technology. Lahmar, M., A. Berecibar, I. Valarche, A. Martin, A. Piessens, L. Batard, C. Freslon-Evain, C. Fernagut, P. Guedat, and M. Mehtali, Journal of Hepatology, 2011. 54: p. S480-S480; ISI[000297625602355].

[WOS]. OV_1223-010512.

24. Self-assembling Peptide Nanotubes with Antiviral Activity against Hepatitis C Virus. Montero, A., P. Gastaminza, M. Law, G.F. Cheng, F.V. Chisari, and M.R. Ghadiri, Chemistry & biology, 2011. 18(11): p. 1453-1462; ISI[000297603600017].

[WOS]. OV_1223-010512.

25. Characterization of Novel, Highly Potent NS5A Inhibitors with QD Dosing Potential and Robust Activity in an HCV Chimeric Animal Model. Nicholas, J.B., B.O. Buckman, V. Serebryany, C.J. Schaefer, K. Kossen, D. Ruhrmund, L. Hooi, N. Aleskovski, A. Arfsten, S.R. Lim, L. Pan, L. Huang, R. Rajagopalan, S. Misialek, and S. Seiwert, Journal of Hepatology, 2011. 54: p. S485-S485; ISI[000297625602367].

[WOS]. OV_1223-010512.

26. Preclinical Characterization of GSK2485852, a Novel HCV Polymerase Inhibitor. Voitenleitner, C., R. Crosby, A. Wang, J. Bechtel, M. Xie, J. Pouliot, E. Woldu, S. Horn, J. Horton, K. Creech, L. Caballo, J. Shotwell, A. Spaltenstein, Z. Hong, and R. Hamatake, Journal of Hepatology, 2011. 54: p. S328-S328; ISI[000297625601396].

[WOS]. OV_1223-010512.

27. Preclinical Characterization of the Novel HCV NS3 Protease Inhibitor GS-9256. Yang, H., C. Yang, Y. Wang, G. Rhodes, M. Robinson, B. Schultz, O. Barauskas, B. Peng, G. Cheng, R. Wang, X. Liu, R. Pakdaman, C. Sheng, C. Kim, and W. Delaney, Journal of Hepatology, 2011. 54: p. S313-S313; ISI[000297625601357].

[WOS]. OV_1223-010512.